FLGT - フルジェント・ジェネティクス （Fulgent Genetics Inc.） フルジェント・ジェネティクスFLGTのチャート
FLGTの企業情報
| symbol | FLGT |
|---|---|
| 会社名 | Fulgent Genetics Inc （フルジェント・ジェネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 フルゲント･ジェネティクス(Fulgent Genetics Inc)は患者治療の質を改善する臨床的に使用可能な診断情報を医者に提供する遺伝子検査を提供する技術会社である。同社はデータ比較･抑制アルゴリズム、適合学習ソフトウェア、先端的遺伝子診断ツール及び統合試験所プロセスを統合する技術プラットフォームを開発した。同社の遺伝子プローブは新規遺伝子をテスト･メニューに組み込み、疾患特異的検査の新パネルを開発し、顧客のために検査をカスタマイズすることを可能とするソフトウェア用に最適化された遺伝的データを生み出すように設計される。 フルジェント・ジェネティクスは米国のバイオテクノロジ―企業。患者ケアの質向上のため、幅広い遺伝子テストを医師に提供。同社の専有技術プラットフォ―ムを開発、遺伝子テストの項目を増やし、より正確で所要時間の短縮を図りながら、価格帯を抑えることを可能にする。本社はカリフォルニア州テンプル・シティ―。 Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing ('NGS') with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company's advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus ('COVID-19'), including NGS and reverse transcription polymerase chain reaction ('RT-PCR') - based tests. The Company has received Emergency Use Authorization ('EUA') from the U.S. Food and Drug Administration ('FDA') for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Company's business is its ability to provide expansive options and flexibility for all clients' unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services. |
| 本社所在地 | 4978 Santa Anita Avenue Temple City CA 91780 USA |
| 代表者氏名 | Ming Hsieh Ming Hsieh |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 626-350-0537 |
| 設立年月日 | 42491 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 98人 |
| url | www.fulgentgenetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/flgt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -4.75700 |
| 終値（lastsale） | 3.97 |
| 時価総額（marketcap） | 71537411.03 |
| 時価総額 | 時価総額（百万ドル） 65.05039 |
| 売上高 | 売上高（百万ドル） 18.83700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 34.44739 |
| 当期純利益 | 当期純利益（百万ドル） -5.65400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Fulgent Genetics Inc revenues increased 1% to $10.1M. Net loss totaled $3M vs. income of $207K. Revenues reflect United States segment increase of 33% to $5.8M Other Countries segment increase of 65% to $2.1M. Net loss reflects Research and development increase of 74% to $2.4M (expense) Selling and marketing increase of 35% to $2.2M (expense). |
FLGTのテクニカル分析
FLGTのニュース
Looking Into Fulgent Genetics''s Return On Capital Employed 2023/03/06 14:46:45 Benzinga
Fulgent Genetics (NASDAQ: FLGT ) brought in sales totaling $67.70 million during Q4 according to data provided by Benzinga Pro . However, earnings decreased 1892.7%, resulting in a loss of $24.08 million. Fulgent Genetics reached earnings of $1.34 million and sales of $105.66 million in Q3. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is … Full story available on Benzinga.com
Fulgent Genetics PT Lowered to $45 at Credit Suisse 2023/03/01 20:50:02 Investing.com
https://www.investing.com/news/pro/fulgent-genetics-pt-lowered-to-45-at-credit-suisse-432SI-3019360
FULGENT GENETICS, INC. – 10-K – Management''s Discussion and Analysis of Financial Condition and Results of Operations. 2023/02/28 22:15:06 InsuranceNewsNet
The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes included in this report and contains forward-looking statements within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act.
Fulgent Genetics Non-GAAP EPS of -$0.48 beats by $0.08, revenue of $67.7M beats by $8.13M 2023/02/28 21:13:00 Seeking Alpha
Fulgent Genetics press release (FLGT): Q4 Non-GAAP EPS of -$0.48 beats by $0.08.Revenue of $67.7M (-73.1% Y/Y) beats by $8.13M.Core Revenue grew 97% year-over-year to $55.0…
Fulgent Genetics Launches Beacon787 Expanded Carrier Screening Panel 2023/02/28 21:05:01 Investing.com
https://www.investing.com/news/assorted/fulgent-genetics-launches-beacon787-expanded-carrier-screening-panel-432SI-3017519
Do investors need to be concerned about Fulgent Genetics Inc. (FLGT)? 2022/12/09 15:24:00 US Post News
Fulgent Genetics Inc. (NASDAQ:FLGT) marked $33.70 per share on Thursday, down from a previous closing price of $37.07. While Fulgent Genetics Inc. has underperformed by -9.09%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FLGT fell by -60.67%, with highs and lows ranging from $109.55 to […]
Fulgent Stock Undervalued And Potential Upside (NASDAQ:FLGT) 2022/12/08 16:30:21 Seeking Alpha
Fulgent is in a favorable position as it shops during a suppressed market. Read more to see why I think FLGT has upside potential.
Piper Sandler Downgrades Fulgent Genetics to Neutral 2022/12/08 08:53:06 Investing.com
https://www.investing.com/news/pro/piper-sandler-downgrades-fulgent-genetics-to-neutral-432SI-2959855
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT 2022/11/28 19:56:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders. If you are a Fulgent shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com. Scott+Scott is investigating
A Look At Fulgent Genetics Inc. (FLGT) Stock Performance 2022/11/26 13:30:00 Stocks Register
Fulgent Genetics Inc. (NASDAQ:FLGT) concluded the trading at $36.89 on Friday, November 25, with a rise of 1.10% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $36.49 and 5Y monthly beta was reading 1.60 with its price kept floating in the … A Look At Fulgent Genetics Inc. (FLGT) Stock Performance Read More »
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm 2022/10/03 01:00:00 GlobeNewswire
NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Sema4 Holdings Corp. (NASDAQ: SMFR, SMFRW), Medtronic PLC (NYSE: MDT), Palantir Technologies, Inc. (NYSE: PLTR), and Fulgent Genetics, Inc. (NASDAQ: FLGT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
DEADLINE ALERT for FLGT, YSG, BCS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders 2022/09/30 17:00:00 GlobeNewswire
BENSALEM, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
FLGT SHAREHOLDER ALERT: Jakubowitz Law Reminds Fulgent Shareholders of a Lead Plaintiff Deadline of November 21, 2022 2022/09/30 09:45:00 PR Newswire
NEW YORK, Sept. 30, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fulgent Genetics, Inc. (NASDAQ: FLGT). To receive updates on the lawsuit, fill out the form:…
Fulgent Genetics, Inc. Class Action Lawsuit: Robbins LLP Reminds Shareholders of Lead Plaintiff Deadline in Class Action Against Fulgent Genetics, Inc. (FLGT) 2022/09/29 20:02:00 Wallstreet:Online
The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Fulgent Genetics, Inc. (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022, for violations of the Securities Exchange Act of 1934. Fulgent provides COVID-19, molecular diagnostic, and genetic testing